Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 11/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29720309 | 1.00 | NLRP3 (0.59) | NLRP3ALDH1A1CYP1A2HDAC4MEN1 | |
| SCHEMBL2885788 | 0.86 | NLRP3 (0.64) | NLRP3ALDH1A1CYP1A2HDAC4MAPT | |
| SCHEMBL4602459 | 0.86 | NLRP3 (0.62) | NLRP3ALDH1A1CYP1A2MEN1KMT2A | |
| SCHEMBL30675594 | 0.86 | NLRP3 (0.62) | NLRP3ALDH1A1CYP1A2MEN1KMT2A | |
| SCHEMBL439465 | 0.86 | HDAC4 (0.71) | NLRP3ALDH1A1CYP1A2HDAC4MEN1 | |
| SCHEMBL441932 | 0.86 | HDAC4 (0.67) | NLRP3ALDH1A1CYP1A2HDAC4MEN1 | |
| SCHEMBL13233238 | 0.84 | HDAC4 (0.65) | NLRP3ALDH1A1CYP1A2HDAC4MEN1 | |
| SCHEMBL7093999 | 0.84 | ALDH1A1 (0.58) | NLRP3ALDH1A1CYP1A2HDAC4MEN1 | |
| SCHEMBL5142374 | 0.83 | ALDH1A1 (0.66) | NLRP3ALDH1A1CYP1A2HDAC4MEN1 | |
| SCHEMBL11014261 | 0.83 | L3MBTL1 (0.67) | NLRP3ALDH1A1CYP1A2HDAC4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101302195-B | Novel synthetic method of 7-hydroxy-3,4-dihydroquinolines | HANGZHOU GREAT FOREST BIOMEDICAL LTD | 2010-06-09 | — | — | CN | claimed |
| CN-101302195-A | Novel synthetic method of 7-hydroxy-3,4-dihydroquinolines | HANGZHOU GREAT FOREST BIOMEDIC (CN) | 2008-11-12 | — | — | CN | claimed |
| CN-112745262-B | Preparation method of brexpiprazole intermediate 7-hydroxy-1H-quinoline-2-ketone | 江苏恩华药业股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-112745262-A | Preparation method of brexpiprazole intermediate 7-hydroxy-1H-quinoline-2-ketone | 江苏恩华药业股份有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-109096249-B | Synthesis method of aripiprazole | 中国科学院兰州化学物理研究所 | 2021-04-09 | — | — | CN | disclosed |
| CN-104356063-A | Preparation method of 7-hydroxy-3,4-dihydro-2-(1H) carbostyril | UNIV EAST CHINA NORMAL | 2015-02-18 | — | — | CN | disclosed |
| CN-101302195-B | Novel synthetic method of 7-hydroxy-3,4-dihydroquinolines | HANGZHOU GREAT FOREST BIOMEDICAL LTD | 2010-06-09 | — | — | CN | disclosed |
| CN-101302195-B | Novel synthetic method of 7-hydroxy-3,4-dihydroquinolines | HANGZHOU GREAT FOREST BIOMEDICAL LTD | 2010-06-09 | — | — | CN | disclosed |
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008150848-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2008-12-11 | — | — | WO | disclosed |
| CN-101302195-A | Novel synthetic method of 7-hydroxy-3,4-dihydroquinolines | HANGZHOU GREAT FOREST BIOMEDIC (CN) | 2008-11-12 | — | — | CN | disclosed |
| CN-101302195-A | Novel synthetic method of 7-hydroxy-3,4-dihydroquinolines | HANGZHOU GREAT FOREST BIOMEDIC (CN) | 2008-11-12 | — | — | CN | disclosed |
| US-20060079690-A1 | Processes for preparing 7-hydroxy-3,4-dihydro-2(1H)-quinolinone and the use in aripiprazole preparation thereof | CHEMAGIS LTD. (IL) | 2006-04-13 | — | — | US | disclosed |
| US-5283336-A | Method for preparation of 7-hydroxy-1,2,3,4-tetrahydroquinoline from 1,2,3,4-tetrahydroquinoline | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1994-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079690-A1 | Processes for preparing 7-hydroxy-3,4-dihydro-2(1H)-quinolinone and the use in aripiprazole preparation thereof | CYP2A7, CYP3A7, CYP3A5 | NLRP3 2189/4885ALDH1A1 93/4885CYP1A2 12/4885 |
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | HTR5A, CRH, CYP17A1 | NLRP3 1940/4885ALDH1A1 643/4885CYP1A2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.